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response, second line therapy. A one-year time horizon was used
to capture all relevant outcomes. Excellent cosmetic outcome
was deﬁned as 100% complete lesion response, with no scarring,
atrophy or induration, and no or slight occurrence of redness or
change in pigmentation compared to adjacent skin. Clinical data
from the trials were subjected to stochastic sensitivity analysis.
RESULTS: From the deterministic model, 69% of nodular BCC
patients had an excellent cosmetic outcome with MAL-PDT at
a cost of £988.47 per patient compared to 36% of patients
treated by excision (£772.91 per patient). Substituting the super-
ﬁcial BCC efﬁcacy data, the cost of MAL-PDT was found to be
£890.35 with a 75% excellent cosmetic outcome. In the sto-
chastic analysis using 1000 simulations, 95% of the ICERs 
calculated were in the range £17 to £2816. CONCLUSIONS:
MAL-PDT is advantageous for cosmetically sensitive areas such
as lesions on the face and has comparable costs.
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OBJECTIVES: Although higher density chemotherapy regimens
could improve treatment outcomes, febrile neutropenia and its
related complications often limit the density of chemotherapy
administration to a suboptimal level. Filgrastim-enabled
chemotherapy regimens administered at a high density were
shown to increase survival among breast cancer patients in a
recent clinical trial (Citron et al, 2003). The high costs of ﬁl-
grastim and time loss of patients and caregivers due to frequent
administration, motivated an economic analysis to compare the
cost-effectiveness of dose-dense therapy with ﬁlgrastim vs. con-
ventional chemotherapy in breast cancer patients. METHODS:
Target Population: Women with node-positive breast cancer.
Time Horizon: Twelve cycles of chemotherapy with lifetime
follow up. Perspective: Societal. Data Sources: The Intergroup
Trial C9741 was the primary source of treatment efﬁcacy, rates
of febrile neutropenia with and without hospitalization, and
other major toxicities. Direct health care cost components and
indirect costs of patient and caregiver time loss were obtained
from literature review. Measurements: Discounted lifetime costs
were estimated based on a decision model. Discounted quality-
adjusted life years (QALYs) was estimated based on the DEALE
method. Incremental cost-effectiveness ratios (ICERs) were cal-
culated for each age group at 5-year interval. RESULTS: Under
the base case assumptions, dose-dense chemotherapy incurred
cost $25,530 higher than conventional therapy over lifetime, and
the average discounted survival beneﬁts were 1.400 QALYs per
patient. This resulted in an average cost-effectiveness ratio of
$19,940 per QALY saved. ICERs were $13,672/QALY in age
group 30–34, and this ratio increased with age to $34,418/
QALY in age group 75–80, indicating a more favorable cost-
effectiveness in younger women. Results of the model were rel-
atively stable when the parameters changed within a reasonable
range. CONCLUSIONS: From a societal prospective, dose-dense
chemotherapy with ﬁlgrastim in breast cancer patients is a cost-
effective improvement compared to conventional chemotherapy.
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OBJECTIVES: This study estimated the costs of treating pan-
creatic cancer and evaluated the additional costs when initial
treatment failed and secondary treatment or terminal care were
needed. METHODS: This claims-based retrospective study used
the MarketScan Commercial and Medicare databases. The study
included patients ﬁrst diagnosed with pancreatic cancer (ICD-9-
CM 157.xx) between January 1, 1999 and November 30, 2000.
A demographically-matched control group was selected at a ratio
of 3 :1. Non-terminal treatment provided to cancer patients upon
diagnosis was categorized as initial treatment. Chemotherapy
switches or additional treatment occurring three months after 
the end of initial treatment were noted as secondary treatment
following treatment failure. Care provided after the onset of
advanced disease, during the 12 months prior to death, or in hos-
pices or nursing facilities was deﬁned as terminal treatment.
Monthly mean costs were adjusted for age, gender, Charlson
Comorbidity Index, region, follow-up length and hospital mor-
tality using ordinary least square regression. RESULTS: The
study included 412 cancer patients and 1236 matched controls.
Mean follow-up was 7.5 months. Adjusted mean monthly health
care costs were $7613 for cancer patients and $334 for controls
(p < 0.05). Inpatient care accounted for the majority of costs
among cancer patients. Approximately half (51.7%) of the eli-
gible patients did not respond to initial treatment, and these
patients incurred $15,000 more per month than patients who
required no additional treatment. The costs of additional treat-
ment and higher initial treatment costs contributed to the cost
burden of treatment failure. CONCLUSIONS: The direct costs
of pancreatic cancer are substantial, and these costs are especially
pronounced when initial treatment fails. The causes of treatment
failure, and the interventions that may prevent or delay these
occurrences, should be investigated further.
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OBJECTIVE: Clinical trial data has proven hormonal therapy
increases survival time when added to a radiation treatment
strategy for locally advanced prostate cancer. The purpose of this
analysis was to assess from the payers’ perspective the cost effec-
tiveness of adding hormonal therapy to radiation therapy when
treating patients with locally advanced prostate cancer.
METHODS: A decision tree model incorporating a Markov
process was developed using DATA 4.0 to determine the cost
associated with a locally advanced prostate cancer patient
gaining an additional year of life as a result of adding goserelin,
a gonadotropin-releasing hormone agonist analogue, to a radia-
tion treatment strategy. Data on the effectiveness of each strat-
egy was obtained from published clinical trials. Costs were based
on the literature and data from the US Centers for Medicaid and
Medicare Services and the UK Department of Health. All costs
and beneﬁts were discounted at ﬁve percent. Conventional and
probabilistic sensitivity analyses were used to assess model
robustness. RESULTS: Over a 9-year period, expected costs of
treatment with radiation alone and with radiation plus gosere-
lin are $7582 and $25,299, respectively, leading to an incre-
mental cost of $17,718 to add hormonal therapy to a radiation
only treatment strategy. In terms of effectiveness, over a nine-
year period, patients treated with hormonal therapy in addition
to radiation therapy gain an average of 0.65 years of life. The
incremental cost effectiveness of combination therapy over radi-
ation alone is $30,887 per additional life-year gained. Varying
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model parameters resulted in incremental cost effectiveness
values ranging from $19,612–$56,120 per additional life-year
gained. CONCLUSIONS: The increase in survival time associ-
ated with adding goserelin to a conventional radiation treatment
strategy comes with additional costs. However, the addition of
goserelin to radiation is cost-effective based on the often cited
$50,000/per life-year gained incremental cost-effectiveness
threshold.
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OBJECTIVES: Results from the ATAC trial indicated that anas-
trozole was superior to tamoxifen for disease free survival (DFS)
in the adjuvant treatment of postmenopausal women with
hormone receptor-positive (HR+) early breast cancer, at median
follow up of 33 months (Lancet 2002;359:2131–39) and 47
months (Cancer 2003;98:1802–10). We calculated the incre-
mental cost-effectiveness ratio (ICER) per life year gained (LYG)
for anastrozole compared to tamoxifen from the US health care
perspective, using the recent 47 month data. METHODS: A
probabilistic Markov model was developed using the updated
ATAC data to project outcomes for both anastrozole and tamox-
ifen to 25 years by extrapolating pooled Kaplan-Meier curves
using parametric statistical methods. It was assumed that recur-
rence rates after the maximum 5-year treatment period would be
equivalent in the anastrozole and tamoxifen groups (a conserv-
ative approach). General mortality data were from US Census
2000. Resource utilization data were obtained from published
literature and structured interviews with 9 US oncologists. Drug
costs were based on average wholesale price and the generic 
cost of tamoxifen. Other unit costs (2002 US$) from standard
national sources and literature were used. Costs and beneﬁts
were discounted at 3%. Sensitivity analyses were conducted.
RESULTS: In a cohort of 1000 patients modeled over 25 years,
anastrozole was estimated to lead to 145 discounted LYG at 
an additional cost of $3.6 million. The discounted ICER of 
anastrozole compared with tamoxifen was estimated to be
$25,169/LYG (95% CI $5925–$48,593). Acceptability curves
showed that the estimated cost/LYG at 25 years was <$50,000
with a probability >90%. The result compared favorably with
commonly accepted thresholds for cost-effectiveness and was
robust to all parameters in sensitivity analyses, including adverse
events. CONCLUSIONS: Based on these ﬁndings, anastrozole
should be a cost-effective alternative to tamoxifen for the adju-
vant treatment of postmenopausal women with HR+ early breast
cancer.
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OBJECTIVE: The use of taxane therapy (paclitaxel and doc-
etaxel) is common for the treatment of metastatic breast cancer
(MBC) and is associated with the development of severe toxici-
ties. These toxicities are often dose limiting and can reduce the
effectiveness of taxane therapy. There are limited data on the eco-
nomic consequences of managing toxicities. The objective of this
analysis is to quantify the direct medical costs of managing
taxane-related toxicities in patients with MBC. METHODS: An
economic model was created to estimate the direct medical costs
associated with the management of taxane-related toxicities.
Model inputs were obtained from published literature, clinical
trial data, and expert opinion. Primary model inputs included
incidence of toxicities, costs of managing toxicities, and the fre-
quency of taxane use in patients with MBC. Costs were inﬂated
to 2003 dollars using the Medical Consumer Price Index.
RESULTS: The estimated costs of managing taxane-related 
toxicities were $7251 per patient treated with paclitaxel and
$17,580 per patient treated with docetaxel. The higher cost for
patients treated with docetaxel was primarily driven by a higher
incidence of adverse events. Disease prevalence estimates and
treatment patterns indicated 55,783 patients with incident cases
of MBC would receive taxane therapy annually in the U.S., with
38% receiving paclitaxel and 62% receiving docetaxel. The
annual direct medical costs associated with managing taxane-
related toxicities in the U.S. are approximately $762.4 million.
CONCLUSIONS: Direct medical costs associated with the man-
agement of toxicities are considerable although disease progres-
sion costs related to the dose-limiting effects of toxicities were
not modeled. Reduction in the incidence and/or severity of
taxane-related toxicities could result in substantially lower
medical expenditures for health care payers.
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OBJECTIVES: Prostate cancer is the most common non-skin
cancer in men in the United States. In 2003, the American Cancer
Society estimated that 220,900 men will be diagnosed with
prostate cancer and 28,900 men would die. Hospitalization 
data provided an opportunity to estimate the economic burden
of prostate cancer and examine what factors were associated
with spending. The objectives are to describe the demographics
of the hospitalized prostate cancer patients, and to explore
factors contributing to spending on prostate cancer hospital-
ization. METHODS: Nationwide Inpatient Sample 1999 data
was used. ICD-9 code for prostate cancer (185) was used to
extract patients with prostate cancer as the primary diagnosis.
2032 men were included in the study. Descriptive statistics on
patient demographics was produced and multivariate regression
was conducted to examine factors associated with hospital
expenditure on prostate cancer. The dependent variable was total
charges. The independent variables included age in years at
admission, died during hospitalization, number of diagnoses 
and number of procedures on this record, location of hospital,
teaching status of hospital, length of stay, admission source,
expected primary and secondary payer, region of hospital, 
and income. SPSS 10.0 was used for all statistical analyses.
RESULTS: The average total charge was $13,242.50. Higher
total charges were associated with the following variables:
younger age, Hispanic origin, admitted from another hospital,
alive at discharge, more procedures performed during hospital-
ization, increased length of stay, and urban, western and non-
teaching hospital, and lower incomes. CONCLUSIONS: This
study provided insight on hospital expenditures for prostate
cancer patients and can be used to develop strategies to reduce
unnecessary total charges.
